07:00 , Apr 28, 2016 |  BC Innovations  |  Translation in Brief

Second chance for grantees

NIH has launched a pilot program with Leidos Holdings Inc. (NYSE:LDOS) to answer the question: is there life after grant rejection? The academic community has long groused about funding limitations through NIH, and even with...
07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

Proellex telapristone: Phase II start

Repros said that this quarter investigators will begin a placebo-controlled, U.S. Phase II trial to evaluate 12 mg Proellex daily for 2-10 weeks prior to surgery in 50 patients with stage I-III breast cancer. The...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

Sanofi neurology, other news

Sanofi's Sanofi U.S. Services Inc. and sanofi-aventis U.S. LLC companies will pay $109 million to the U.S. Attorney's Office, District of Massachusetts, the U.S. Department of Justice and multiple states to resolve a 2010 False...
07:00 , Mar 17, 2008 |  BioCentury  |  Regulation

Tallying the ESA votes

Tallying the ESA votes Panelist [TVM = temporary voting member] Title [1] Continue CIA mktg? [2a] Restrict to sm cell lung cancer? [2b] Contraindicate:with potentially curative treatment? [2c] Contraindicate:breast/ head & neck cancers? [3a] Require...
08:00 , Dec 10, 2007 |  BioCentury  |  Regulation

Tallying the votes

Tallying the votes Tallying the votes FDA's Oncologic Drugs Advisory Committee voted 5-4 last week that Genentech (DNA) has not demonstrated a favorable risk-benefit ratio for Avastin bevacizumab plus paclitaxel for first-line treatment of metastatic...